This article provides key insights and suggested best practices for managed care to improve patient care in MPS disorders, which may also be relevant to other rare and ultra-rare conditions.
AMCP Submits Comments to CMS on Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency
The Academy of Managed Care Pharmacy (AMCP) is pleased provide comments to the Centers for Medicare & Medicaid Services (CMS) in response to the proposed rule “Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency [CMS-4187-P]” published in the Federal Register on October 18, 2018. AMCP appreciates the opportunity to leverage our members’ expertise in offering feedback on this proposed rule and we look forward to continued dialogue with CMS on ways to improve drug price transparency and make medications more affordable for patients.
Related
As part of a multi-year RWE initiative, AMCP Research Institute partnered with IQVIA, payers, pharmaceutical companies, and others to design payer-focused RWE standards that were published in JMCP in September, 2025.
AMCP’s guidance translates CMS’s expectations for patient centered, evidence informed formulary decisions into practical steps payers can act on today without adding unnecessary burden to P&T workflows.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
